Investment in diabetes-focused AI companies exceeds $361 million in 2023
London, UK - September 18, 2023: Investments in diabetes-focused AI companies have reached $361.6 million in 2023, according to a new report by Aging Analytics Agency, a UK-based market intelligence agency focused on longevity analysis and a subsidiary of Deep Knowledge Group.
The influx of financial support is a testament to the transformative potential of AI in the fields of diabetes management and treatment.
The report highlights the trend of AI investment in diabetes, which has experienced a surge since 2015, maintaining a consistent growth pattern. During this seven-year period, there was a climb from a modest $4 million reported in 2015 to $361 million in 2023, showcasing a remarkable 79-fold increase.
AI has revolutionized diabetes care in various ways including through the integration of wearable devices, automation of blood sample analysis, risk assessment, efficient patient data management, and the diagnosis of diabetic retinopathy, a prevalent eye complication.
In light of these findings, Maria Shmelova, Director of Strategy and Business Development at Deep Knowledge Group, stated: "AI is not just a promising tool but a necessary one in addressing the challenges in diabetes. Our analysis shows a clear upward trend in the adoption and integration of AI in diabetes diagnosis and treatment, and we believe this will continue to accelerate."
The United States and China are the most prominent leaders in the field of AI in Diabetes, based on both the number of clinical trials performed and ongoing patented technologies.
Notable achievements in AI for diabetes include the development of self-learning AI for blood glucose level prediction, improved management applications, and various technological advancements, with a focus on optimizing the process of diagnosis, monitoring, and treatment, making it more accessible.
The application of AI in the field of diabetes is closely related to partnerships that enhance both diagnostics and research. These partnerships involve collaboration with representatives from Big Pharma and brand-new start-ups, mainly focused on AI technology or specific diabetic condition research.
Aging Analytics Agency is the world’s premier provider of industry analytics on longevity, precision and preventive medicine, economics of aging, and the convergence of technologies such as AI, blockchain, digital health, and their impact on the healthcare industry.
To view the full report, please visit https://www.aginganalytics.com/ai-in-diabetes-2023
